secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2023-09-28T23:59:59+00:00
Accession:  0001193125-23-245807
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Biopharma regains Nasdaq compliance with $28.6M equity offering
-----------------------------------------------------------------------

- Regained compliance with Nasdaq minimum stockholders' equity rule via $28.6M net proceeds from August 2023 offering.
- As of June 30, 2023, stockholders' equity was below $2.5M requirement; offering resolved deficiency.
- Offering included 875,949 common shares, 15,126,226 pre-funded warrants, and 16,002,175 common warrants at $1.93 per unit.
- Nasdaq will continue to monitor compliance; non-compliance at next report could lead to delisting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312523245807/0001193125-23-245807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312523245807/d512438d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-245807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer